October 31, 2025
Clozapine is a highly effective atypical antipsychotic, but it’s not without drawbacks (Table 1). Historically, patients, prescribers and pharmacies were required to enroll in the Clozapine REMS program due to the drug’s potential to cause agranulocytosis. The REMS program was officially eliminated on June 13th, 2025, though the FDA still recommends that prescribers monitor absolute […]
Read MoreAugust 19, 2025
Our hospice partners occasionally ask how to convert patients from one antiseizure medication (ASM) to another. These requests are usually driven by cost or formulary considerations, but other common reasons include lack of efficacy, intolerable adverse effects, and problematic drug-drug interactions. Ideally, formulary / cost shouldn’t be the sole basis for rotating to an alternate […]
Read MoreAugust 21, 2024
Originally published on HospiceNews.com, OnePoint Vice President – Client Services Kenny Judd sat down with Hospice News to discuss discuss the state of hospice pharmacy service nationally, the challenges local providers face in caring for this unique patient population and the role which OnePoint plays in ensuring providers have a reliable, sustainable community-based and hospice-dedicated […]
Read MoreApril 7, 2023
The oral route is by far the most common way medications are administered – even in the hospice setting. However, it’s not always feasible for a number of reasons – dysphagia, nausea/vomiting, or obtundation to name a few.1,2 Administering drugs subcutaneously (SC/SQ) is one method used to overcome patients’ inability to swallow and absorb oral […]
Read MoreFebruary 22, 2023
One of the problems with starting traditional antidepressants in hospice patients is that they might take too long to start working (typically a few weeks) and/or reach their full effect (up to 8 weeks). To get around this, some hospice clinicians will prescribe methylphenidate or ketamine to treat depression more rapidly; the onsets are about […]
Read More